rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Effect of Non-chirurgical Periodontal Treatment on the Immune System From a Gender Perspective
Status: Not yet recruiting

The goal of this observational study is to evaluate non-surgical periodontal treatment in women and men with periodontitis with and without obesity. The main questions it aims to answer are:

If non-surgical periodontal treatment of patients with chronic periodontitis can modulate the innate and adaptive immune response taking into account patient gender and the coexistence of obesity
If there are specific miRNAs that can regulate this immune response and can be considered as suitable biomarkers and therapeutic targets.

Obese or non-obese participants with periodontitis will receive non-surgical periodontal treatment, consisting of oral health guidance and mechanical periodontal debridement throughout the mouth using an ultrasonic device and manual curettes. Researchers will compare four groups: obese women, non-obese women, obese men, and non-obese men, to clarify the involment of immune response after treatment, considering the coexistence of obesity and potential gender differences.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Men/Women with periodontitis:  Periodontitis will be diagnosed according to the definition of the Centers for Disease Control and Prevention / American Academy of Periodontology (CDC/AAP).  Men/Women with obesity:  Body mass index (BMI) ≥30 kg/m2 (WHO 2000)  Exclusion Criteria:  Having fewer than fourteen teeth, Having infectious diseases Having other oral inflammatory diseases, Having received periodontal treatment in the past six months or antibiotics in the previous three months, undergoing systemic anti-inflammatory treatment, Pregnancy or lactation Serious illnesses, congenital adrenal hyperplasia, virilizing tumors, hypothyroidism, Cushing's syndrome, prolactinomas, cardiovascular diseases, or diabetes mellitus. Alcohol or drug abuse Psychiatric disorders. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - GenderBased: Yes - GenderDescription: According to presence of periodontitis and obesity. - MinimumAge: 18 Years - MaximumAge: 69 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Primary care clinic - SamplingMethod: Non-Probability Sample
Intrapartum Ultrasound in Labor: Sonography Only, Few Internal Examinations
Status: Recruiting

This is a prospective, randomized trial to determine whether the use of sonographic parameters during labor results in less intrapartum infection compared to traditional invasive examination. Other secondary outcomes include maternal satisfaction and overall birth outcomes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Pregnant women of at least 18 years of age with a singleton in the cephalic position Spontaneous onset of labor; births after induction of labor with otherwise suitable inclusion and exclusion criteria are also permitted.  Exclusion Criteria:  Emergency situations such as maternal or fetal bleeding Indication for urgent delivery by caesarean section Pathological cardiotocogram non-cephalic positions under 18 years of age women giving birth who are unable to give consent - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 18 Years - MaximumAge: 60 Years - StdAgeList: Adult
Relationship Between Smartphone Addiction and Temporomandibular Joint Disorders Among Adults in Egypt.
Status: Not yet recruiting

Cross sectional study to investigate the relation between Smartphone addiction and temporomandibular disorders among youth population in Egypt. An online- based questionnaire study. A 296 participants who are Egyptians with age between18 and 35 years old without prior neck and upper extremity related diseases, orofacial trauma or surgeries, history of rheumatoid arthritis or congenital musculoskeletal problems. An online- based questionnaire will be sent through different social media platforms, it will include three screens, the first includes the consent form, the second includes the demographic data (year of birth, current educational status, gender and geographic information ), and the third page includes questionnaires

.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  both males and females adults Their ages between18 and 35 years old ability to use Smartphone  Exclusion Criteria:  any neck and upper extremity related diseases orofacial trauma or surgeries history of Rheumatoid arthritis congenital musculoskeletal problems. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 35 Years - StdAgeList: Adult - StudyPopulation: community sample - SamplingMethod: Probability Sample
Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.
Status: Recruiting

The goal of this prospective randomized controlled study is to study the safety and efficacy of intralesional acyclovir compared to cryotherapy in plantar warts. The main questions needed to be answered are:

Is Intralesional acyclovir safe for plantar warts?
Is Intralesional acyclovir more efficient in treating plantar warts compared to cryotherapy?

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients aged 18 years or older, of both genders, with plantar warts  Exclusion Criteria:  Patients on systemic treatment for warts eg. Acitretin, Acyclovir Hypersensitivity to Acyclovir Previous treatment to the same wart during the last 3 months Immunocompromised patients (as HIV, steroid intake, uncontrolled diabetes, etc.) Pregnant and breastfeeding females Cognitively impaired patients - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Effect of Antioxydant-enriched Media on Blastocyst Euploidy Rates.
Status: Not yet recruiting

One of the most sensible factors in IVF culture conditions is the susceptibility of gametes and embryos to an induced increase in reactive oxidative species (ROS) caused by the artificial environment. This study aims to evaluate the impact of using antioxidant-supplemented media during culture to evaluate embryo ploidy rates in a prospective randomized trial using sibling oocytes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients undergoing assisted reproductive technology cycles when ICSI is indicated. Patients when Iin vitto fertilization (IVF) is also performed will be included as far as there are enough oocytes for ICSI randomization. However, IVF oocytes will not be used for the study. Maternal age 18-43 years old. PGT-A cycles with only trophectoderm biopsies on day 5/6/7. Patients with more than 6 COCs expected for ICSI. Body mass index <35. Fresh and frozen ejaculated sperm.  Exclusion Criteria:  PGT-M cycles Fresh and frozen testicular sperm. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - GenderBased: Yes - MinimumAge: 18 Years - MaximumAge: 43 Years - StdAgeList: Adult
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Status: Recruiting

The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  request for cryopreserved ovarian tissue transplantation; premature ovarian failure or irregular mentrual cycles; negative test for HIV, HBV, HCV, Treponema pallidum; negative PAP test; oncological authorization; absence of neoplastic contamination in the cryopreserved ovarian tissue; Informed consent  Exclusion Criteria:  neoplastic contamination in cryopreserved ovarian tissue; history of endometriosis; endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2); body mass index (BMI) >30 kg/m2; circulating platelet level < 150,000 / mml; bacterial infection; ongoing use of anticoagulants; bleeding diathesis. - HealthyVolunteers: No - Gender: Female - StdAgeList: Child, Adult, Older Adult
Rotofunc - Non-traumatic Shoulder Instability and Total Rotator Cuff Function
Status: Recruiting

The goal of this clinical trial is to test the effect of a novel assessment and treatment strategy for young adults with severely disabling non-traumatic shoulder instability. The main question it aims to answer is if this treatment will substantially change the patients shoulder function to a more stable and controllable state and thereby give a higher quality of life. Participants failure in active shoulder muscle function will be assessed and exercises will be selected individually. Patients will be asked to perform the exercises twice per day. At clinical visits to a specialized physiotherapist the exercises will be upgraded to restore full dynamic stability throughout shoulder movement range. The active treatment period will be 4 months. Researchers will compare two groups. One group will start directly after a baseline assessment is fulfilled. The other group will receive the treatment with a delay of 4 months to evaluate if the selected exercises can substantially change the shoulder stability compared to no treatment, the natural course of the condition.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  young adults, non traumatic as well as non-controllable, positional, functional shoulder instability according to Moroder et al. demonstrating a lack of ≥ 20%, active, dynamic control compared with the total passive range of motion in shoulder rotation with or without previous shoulder stabilizing surgery Understanding the Swedish language well, in speaking, in reading and writing.  Exclusion Criteria:  Other significant shoulder pathologies, patients diagnosed with severe systemic connective tissue, congenital anatomic abnormalities, or psychiatric diagnoses according to previous medical records <60% adherence to assigned exercises - HealthyVolunteers: No - Gender: All - MinimumAge: 16 Years - MaximumAge: 35 Years - StdAgeList: Child, Adult
Superiority Trial Between Sotair® Device Attached to Manual Resuscitator Versus Ventilation Alone
Status: Recruiting

Effective respiratory ventilation is achieved by moving the right amount of air to and out of the lungs while keeping the pressures at a safe level. A disposable safety device, Adult Sotair®, was created to improve manual ventilation delivery. In this superiority study, the investigators will perform two-group cross over randomized design to test the superiority of the Adult Sotair® device compared to manual ventilation alone.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult patients who are scheduled for non-emergency surgery with general anesthesia (w/artificial airway) at Rhode Island Hospital. American Society Of Anesthesiologists Physical Status 1 and 2  Exclusion Criteria:  American Society of Anesthesiologists Physical Status >3 (e.g. respiratory disease) Oropharyngeal or facial pathology - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Blood Flow Restriction in Improving Muscle Strength of Patients With Hemophilic Ankle Arthropathy
Status: Recruiting

Background. The main physical sequela of patients with hemophilia is the development of a progressive, degenerative intra-articular lesion, known as hemophilic arthropathy). This sequela is manifested by chronic pain, limited range of motion, axial abnormalities, and periarticular muscle atrophy.

Objective. To assess the safety and effectiveness of an intervention through blood flow restriction, regarding the frequency of bleeding and the improvement in muscle activation and strength, range of motion, stability, joint pain, joint status and the perception of quality of life in patients with hemophilic ankle arthropathy.

Study design. Randomized, multicenter, single-blind clinical study. Method. 32 patients with hemophilia A and B will be recruited in this study. Patients will be recruited in 4 regions of Spain. The dependent variables will be: bleeding frequency (self-registration), pain (measured with the visual analog scale and pressure algometer), quality of life (SF-36 scale), joint status (Hemophilia Joint Health Score scale), strength (dynamometer) and muscle activation (surface electromyograph), range of motion (goniometer) and stability (The Single Leg Stance Test). Three evaluations will be carried out: pre-treatment, post-treatment and after a follow-up period of 4 weeks.

Expected results. Observe the safety of blood flow restriction in hemophilia patients. To analyze the efficacy of blood flow restriction in improving muscle strength and activation, range of motion, chronic pain, stabilit, and the perception of quality of life in patients with hemophilic ankle arthropathy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed with hemophilia A and B People with a medical diagnosis of hemophilic ankle arthropathy Patients over 18 years of age Paceinets in prophylactic or on-demand treatment regimen with FVIII/FIX concentrates. Failure to sign the informed consent document  Exclusion Criteria:  Patients with neurological or cognitive alterations that prevent understanding of the questionnaires Amputee patients, epileptics or patients with severe vision problems Patients who are receiving physiotherapy treatment at the time of the study - HealthyVolunteers: No - Gender: Male - MinimumAge: 18 Years - MaximumAge: 55 Years - StdAgeList: Adult
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
Status: Not yet recruiting

Asthma is a common lung condition that causes occasional breathing difficulties and affects around 5.4 million people in the UK of all ages. Common symptoms can include wheezing when breathing, breathlessness, a tight chest and coughing. However, these symptoms can get worse and lead to an asthma attack which can be fatal.

There is currently no cure for asthma but there are treatments that can help keep the symptoms under control. The main types of treatment include reliever inhalers used when needed quickly to reverse asthma symptoms for a short time, and preventer inhalers that are used everyday to prevent symptoms for starting. Unfortunately, not all patients are able to control their asthma on these treatments alone. Biologic treatments, also known as monoclonal antibodies, have been introduced to treat certain types of severe asthma over recent years. These specialist treatments use antibodies produced from cells in a laboratory to help reduce inflammation and might offer the possibility of higher levels of disease control including the reduction or absence of symptoms and normal lung function. This higher level of disease control is called remission.

This study aims to understand whether or not remission is possible in patients with severe asthmas treated with biologics in the NHS. This study will take place a 4 specialist asthma centres in the UK and seeks to include retrospective data from approximately 450 adult patients that were treated with biologics as part of routine care between 01 October 2021 and 30 September 2022. Data will be collected directly from medical records and entered into the study database in a pseudonymised format by members of the direct care team ready for analysis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Initiated on a biologic treatment for SA between 1st October 2021 and 30th September 2022 Patients who received ≥1 dose of biologic treatment Patients aged ≥18 years at index  Exclusion Criteria:  Patients who were involved in any interventional clinical trial during the study period (+/- 12 months from index). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 130 Years - StdAgeList: Adult, Older Adult - StudyPopulation: The source population for this study will be patients who were treated with a biologic for severe asthma in UK NHS centres between October 2021 and September 2022 - SamplingMethod: Non-Probability Sample
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
Status: Recruiting

It is a randomized, single-center, controlled trial to evaluate the effectiveness of oral immunotherapy with low-dose sesame protein compared with standard treatment (elimination diet) in patients with sesame allergy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age between 3 and 17 years, IgE-mediated sesame allergy confirmed with positive skin prick tests with sesame allergens (diameter of the wheal greater than 3mm) and/or specific IgE level greater than 0.35-kilo units of Allergen per liter (kUA/l), Allergic reaction to sesame protein during oral food challenge (OFC), Signed Informed Consent by parent/legal guardian and patient aged >16 years old, Patient's and caregivers' cooperation with the researcher.  Exclusion Criteria:  No confirmed sesame allergy, Negative OFC with sesame protein (maximum dose 4000mg), Severe asthma, uncontrolled mild/moderate asthma: forced expiratory volume at one second (FEV1)<80% (under 5. percentile), FEV1/forced vital capacity (FVC)<75% (under 5. percentile), hospitalization due to asthma exacerbation within last 12 months, Current oral/sublingual/subcutaneous immunotherapy with other allergens in the first year of immunotherapy, Eosinophilic gastroenteritis, A history of severe recurrent anaphylaxis episodes, Chronic diseases requiring continuous treatment, including heart disease, epilepsy, metabolic diseases, diabetes,  Medication:  oral, daily steroid therapy longer than 1 month within the last 12 months, at least two courses of oral steroid therapy (at least 7 days) within the last 12 months, oral steroid therapy longer than 7 days within the last 3 months, any biological treatment, therapy with β-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel inhibitors, Pregnancy, No consent to participate in the study, Lack of patient or caregiver cooperation. - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Years - MaximumAge: 17 Years - StdAgeList: Child
Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Multiple Sclerosis in a Clinical Setting
Status: Not yet recruiting

The primary objective of the study is to validate the safety and performance of the ABLE Exoskeleton device in people with multiple sclerosis during a 10-session gait training program in a clinical setting. Furthermore, the potential effects of the training on walking, and balance function, general health status, user satisfaction, and quality of life will be assessed.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  18 to 70 years of age. Diagnosed with MS. Currently receiving treatment as an inpatient or outpatient at one of the investigational site. Ability to give informed consent.  Exclusion Criteria:  Significant osteoporosis that may increase the risk of fracture. Unresolved fractures in the pelvis or extremities, or history of fragility fractures in the lower extremities in the last 2 years. Spinal instability (or spinal orthoses, unless authorized by a physician). Severe spasticity: Level 4 on the Modified Ashworth Scale. Orthostatic hypotension. Inability to tolerate a minimum of 30 minutes of standing. Uncontrolled autonomic dysreflexia. Medically unstable Unstable cardiovascular system (CVS), hemodynamic instability, untreated hypertension (SBP>140, DBP>90 mmHg), unresolved deep venous thrombosis (DVT). Serious comorbidities, including any condition that a physician deems inappropriate for use of the ABLE Exoskeleton or to complete participation in the study. Skin integrity problems on the contact surfaces of the device or that would prevent sitting. Grade I or higher on EPUAP (European Pressure Ulcer Advisory Panel, 2019) on areas that will be in contact with the exoskeleton. Colostomy. Anthropometric measurements outside the values compatible with ABLE Exoskeleton. In particular, height not between 1.5-1.9 m, or weight over 100 kg. Anatomical constraints (such as eg length differences, users unable to position themselves inside the device) that are incompatible with the device. Restrictions in range of motion that prevent normal gait from being achieved or preventing the completion of a normal transition from sitting to standing or standing to sitting. Heterotopic ossification Known pregnancy or breastfeeding Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult
Phase I Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis
Status: Not yet recruiting

The study is being done to determine if treatment with a novel form of light therapy is tolerated in patients with progressive multiple sclerosis. The goal of this trial to establish the safety profile of this light therapy while generating data on its impact on fatigue, as well as its mechanism of action. Fatigue is often a complex symptom in multiple sclerosis, without any FDA-approved direct therapy. Fatigue is traditionally treated with symptom management through a multidisciplinary team.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age ≥ 18 years old Diagnosis of PPMS or SPMS according to the 2017, or 2010 Revised McDonald Criteria In the opinion of the investigator, able to complete study procedures Must be on a stable dose of an FDA-approved disease modifying therapy for at least 3 months prior to screening  Exclusion Criteria:  Pharmacological and non-pharmacological mood and fatigue treatment changes within the previous three months prior to screening Based on the Investigator's judgement, patients with a history of significant other medical condition that may interfere with the conduct of the study, or interpretation of the study results History of any clinically significant abnormality in hematology, blood chemistry, or examination not resolved by the baseline visit which according to the investigator can interfere with study participation Positive drug screen for cocaine, or phencyclidine, or known alcohol abuse within 30 days of the trial Females who are pregnant, have a positive pregnancy test, are nursing, or who plan to get pregnant during the course of this clinical trial Patient taking melatonin analogues without appropriate washout, defined as five half-lives of the medication, or within 14 days of screening, whichever is longer New or adjusted prescription medication within 14 days of the baseline An investigator verified MS relapse within the previous year Presence of a gadolinium-enhancing demyelinating lesion within the last year Optic neuritis within the previous 3 months Travel across two time zones within 3 months of study screening - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult